keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP and functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis, which is induced by histamine, 5-HT, or Forskolin. Additionally, CNP exhibits strong endothelial-derived relaxation properties and acts as a growth inhibitor.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,820 | 待询 | ||
5 mg | ¥ 7,320 | 待询 | ||
10 mg | 待询 | 待询 | ||
50 mg | 待询 | 待询 |
产品描述 | C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP and functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis, which is induced by histamine, 5-HT, or Forskolin. Additionally, CNP exhibits strong endothelial-derived relaxation properties and acts as a growth inhibitor. |
体外活性 | C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1]. PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) AUC 0→∞ (pM?min/mL) MRT 0→∞ (min) T 1/2 (min) CL tot (mL/min/kg) Vd ss (mL/kg) 20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC 0→∞ (pM?min/mL) MRT 0→∞ (min) T 1/2 (min) BA (%) 50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9 Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL tot =total clearance, T 1/2 =half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3]. |
分子量 | 2311.64 |
分子式 | C95H158F3N27O30S3 |
CAS No. | 1966153-17-2 |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
C-Type Natriuretic Peptide (CNP) (1-22), human TFA 1966153-17-2 CType Natriuretic Peptide (CNP) (122), human TFA C-Type Natriuretic Peptide (CNP) , human TFA C Type Natriuretic Peptide (CNP) (1 22), human TFA Inhibitor inhibitor inhibit